Statins for the primary prevention of cardiovascular disease
50 results
1 - 50
Statins for the primary prevention of cardiovascular disease
Statins for the primary prevention of cardiovascular disease 
USPSTF 2022: updated review of statins for the primary prevention of cardiovascular disease- Treatment of dyslipidaemias
- Comprehensive treatment and follow-up of type 2 diabetes
- Statins ineffective for primary prevention in patients 75 years or older without diabetes
- Statins of modest benefit for low- to moderate-risk persons (NNT ~ 80)
- Statins effective for LDL 190 mg/dL or higher, regardless of risk level
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
- Fibrates for primary prevention of cardiovascular disease events
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- Statins for primary prevention of venous thromboembolism
- PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
- More nuanced guidelines for lipid lowering to prevent CV disease
- Ezetimibe for the prevention of cardiovascular disease
- Statins for hyperlipidemia reduce all-cause mortality
- Fibrates for primary prevention of cardiovascular disease
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients
- Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
- PCSK9 inhibitors for prevention of cardiovascular disease
- Statins for the primary prevention of venous thromboembolism
- Low-dose aspirin for prevention of vascular events in type 2 diabetes
- Hypertension: investigations, treatment initiation and non-pharmacological treatment
- Preoperative statin therapy for adults undergoing cardiac surgery
- Fibrates for secondary prevention of cardiovascular disease and stroke
- Statin therapy decreases cardiac events
- Mobile phone‐based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
- Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease
- Efficacy and safety of cholesterol lowering by statins
- Dietary advice for reducing cardiovascular risk
- Interventions to improve adherence to lipid‐lowering medication